ANDREW SMEJDIR: Open Payments
NPI 1891459483 · SHERMAN, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$541 in 25 payments from 12 companies in 2025. Trend: 2023 $1,283 · 2024 $1,257 · 2025 $541
Food & beverage: $448Education: $93
| Company | Payments | Amount |
|---|---|---|
| Regeneron Healthcare Solutions, Inc. | 11 | $233 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $74 |
| Grifols USA, LLC | 2 | $37 |
| Amgen Inc. | 1 | $34 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $27 |
| AstraZeneca Pharmaceuticals LP | 1 | $25 |
| GlaxoSmithKline, LLC. | 1 | $21 |
| Genentech USA, Inc. | 1 | $20 |
| Lilly USA, LLC | 1 | $20 |
| Octapharma USA, Inc. | 1 | $17 |
Products named: DUPIXENT, CUVITRU, NEFFY, TAKHZYRO, TEZSPIRE, TRELEGY ELLIPTA, Xolair, Xembify.
Industry payments across TX — which companies pay providers there.
